Switching on kinases: oncogenic activation of BRAF and the PDGFR family. - Wikidata - awgldk - TriplyDB

Switching on kinases: oncogenic activation of BRAF and the PDGFR family.

Switching on kinases: oncogenic activation of BRAF and the PDGFR family.

http://www.wikidata.org/entity/Q45041454

about

Cell signaling by receptor tyrosine kinases ERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancer Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression Ten things you should know about protein kinases: IUPHAR Review 14 Recent applications of chemosensitivity tests for colorectal cancer treatment The role of suppressors of cytokine signalling in human neoplasms Activation of tyrosine kinases by mutation of the gatekeeper threonine Structural Basis for c-KIT Inhibition by the Suppressor of Cytokine Signaling 6 (SOCS6) Ubiquitin Ligase Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor Hotspot mutations in KIT receptor differentially modulate its allosterically coupled conformational dynamics: impact on activation and drug sensitivity Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT A network-based gene-weighting approach for pathway analysis.An in silico study of the molecular basis of B-RAF activation and conformational stability.Bi-directional SIFT predicts a subset of activating mutations.Tyrosine kinases in inflammatory dermatologic disease.A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1 Leucine motif-dependent tyrosine autophosphorylation of type III receptor tyrosine kinases.The multifaceted role of curcumin in cancer prevention and treatment.Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.Targeting the mitogen-activated protein kinase cascade to treat cancer.Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.Structure of extracellular signal-regulated kinase 2 in complex with ATP and ADP.KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.Raf kinases: oncogenesis and drug discovery.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Emerging drugs for the treatment of soft tissue sarcomas.The genomic landscape of response to EGFR blockade in colorectal cancer.Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report CRAF R391W is a melanoma driver oncogene Pan-Cancer Analysis of Mutation Hotspots in Protein Domains.Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations Individualized therapy for metastatic colorectal cancer.Potential biofluid markers and treatment targets for renal cell carcinoma.Novel targets in the treatment of advanced melanoma: new first-line treatment options.Personalized medicine in hematology - A landmark from bench to bed Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors.Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain.A new mechanism of BRAF activation in human thyroid papillary carcinomas.

P2860

Q24598357-F100FC52-B79E-4C8B-ADE9-6A4D40D47EBB Q24810389-01148F09-CF57-4F84-BAE0-1792C552DD9C Q24813774-904354C8-B467-4C20-B4B5-0D5A5A8171CF Q26849417-EA08B530-E800-44F6-BA34-013381B1DFD2 Q26851075-D609ED57-1706-44B9-8E77-49E5AE9D1879 Q27026783-240B7745-41CD-4396-8E99-95C1E7A95FA7 Q27652166-B86F173D-D077-404D-8E84-C3B1A0023C18 Q27665424-6B8B4EC3-6812-42AE-A19A-D336DE1B4C78 Q27851455-DB3FE7AC-DFDE-4465-99C5-861E81E04741 Q28541374-8DADD2DF-1D7B-4BC9-A02D-F4064BC10CA0 Q28553167-2B8C7C01-4A0F-4CE2-B1A3-70061261C40F Q30506064-6CE3BF9B-33B8-4938-939E-8949DFA7C69B Q33485591-C7F60C4D-39FB-4B35-8E6A-59B4B8257B4B Q33518531-C1A2E058-5CDB-4CAC-90BF-7E4EA1470BEB Q34166503-6CC3D68F-96E0-4E7F-8DD6-FA47DD178812 Q34333820-1AF566F6-6F5A-4737-A272-A6E56E3EBCC8 Q34595463-9AC1DB77-675E-44BF-95AF-3F5B10B9F17C Q34667865-419CEA30-E0C0-4BEC-BB8D-F05184DB260E Q34669746-45973157-4922-49DB-B5D7-0CE6F694CDD4 Q35168745-2E0BFC03-19AF-4BC4-BA57-40B98668941B Q35895558-8C118A65-6745-41DF-8EE7-1E1E3EC0FD39 Q35968411-C79168E3-0246-403F-8849-AC524DE8372E Q36245376-41DB3CCE-5AA8-47B0-9555-03ACFC92C07F Q36433601-D7214692-F062-4DA9-9799-F0FB878E72ED Q36536625-4E1B9617-9766-4F73-BF4D-95636BEE3B92 Q36559414-A6E4A65E-37DE-4AE5-B1B2-3BF32F78E4FD Q36589865-810E7946-61DB-4936-9167-7CF0E4D1D4A4 Q36758596-D02FB697-5239-4C5C-96F8-8FC6E47BEC87 Q36930106-A13135F9-D6D3-425B-A208-2D8BB761B4FD Q36960097-5403322B-C467-4C31-8BE4-34FEA1C31085 Q36980239-C5CB11FD-7388-480D-A4AA-E176501F3A0E Q37170860-80114FC7-B101-4DB0-BCC8-12D73B18965C Q37326191-D62AC92E-98C3-4390-BB33-843CDC657A9E Q38092886-04564331-DA56-4683-B5E0-85B0A09DBDF9 Q38094918-E6D65B57-57C7-4A12-9EC5-4384723070BD Q38095228-EBCCED7A-21EF-4913-A3D7-B6C532D4444B Q38263199-9585AECF-95C6-4ED1-9B6B-3B4C5228A165 Q39186932-BE4B0D2F-571A-440C-90D0-4954A1A989E5 Q39628474-9678F171-1688-4B07-8202-E7966169C29C Q40743581-C5D88210-E010-4698-A8D8-E7EE6270FF11

P2860

Switching on kinases: oncogenic activation of BRAF and the PDGFR family.

http://www.wikidata.org/entity/Q45041454

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Switching on kinases: oncogenic activation of BRAF and the PDGFR family.

@en

Switching on kinases: oncogenic activation of BRAF and the PDGFR family.

@nl

type

label

Switching on kinases: oncogenic activation of BRAF and the PDGFR family.

@en

Switching on kinases: oncogenic activation of BRAF and the PDGFR family.

@nl

prefLabel

Switching on kinases: oncogenic activation of BRAF and the PDGFR family.

@en

Switching on kinases: oncogenic activation of BRAF and the PDGFR family.

@nl

P1433

Q45041454-B2A3258E-5FFD-4E72-8E22-D4DB10662A77

P1476

Q45041454-81670974-16A7-48AF-B772-B37503DED8BE

P2093

Q45041454-5D86A86A-E714-4704-A637-2F86D64B2BD5

Q45041454-6CE7DCA6-DF15-4DD2-94C3-22DA3D0B78EA

Q45041454-B54C3E0A-7DA6-40FC-8A85-2367B51FEC7E

P2860

Q45041454-010E99A3-F4D7-4664-8C70-D5094EBC9137

Q45041454-03E6BAB8-AAD8-4D30-AB4C-FF16890D733A

Q45041454-056F089D-1618-4B1E-8817-4F8E966FDA0A

Q45041454-0A047F64-0742-4311-87FD-DC7EA3D0AFD2

Q45041454-0C01D2B0-DBB5-4DE8-B4BD-DF2CBDA50F84

Q45041454-0C5E3E6F-F9C2-407D-9E35-C327081F9340

Q45041454-177F1EE1-F498-4D9E-844C-BB6619D70130

Q45041454-254DD1BE-62B2-4149-8A4D-321243615B54

Q45041454-26D80011-F724-4679-9E2F-C503FCF6FF8E

Q45041454-301D2707-4C49-4CDD-BD6D-E11D81F7F9B9

P2888

Q45041454-9A07972E-736F-41DF-82AB-100DF37804A4

P304

Q45041454-FAE885E7-9C59-4B0E-BB01-664BB3DAFB56

P31

Q45041454-5350F11B-4E4E-4FD4-ABAF-0A9FDB5F2EC1

P356

Q45041454-5D371C59-973A-4C63-B8D3-C58AF51806EE

P407

Q45041454-BBE2B962-98D8-43B9-A902-F5CB55C30E69

P433

Q45041454-34F98B92-A18C-4729-BCBB-F0F355CD1D82

P478

Q45041454-E503F483-45A4-41BC-AF96-8847F69C06DB

P577

Q45041454-DC4887EC-DC9E-4802-9924-247DEFDCA85C

P6179

Q45041454-94C205CF-9A9D-4216-9A4B-7B85E1FBE70F

P698

Q45041454-1C6ECA90-B08E-47B4-8FE1-AFA54E53140A

P356

P1433

Nature Reviews Cancer

P1476

Switching on kinases: oncogenic activation of BRAF and the PDGFR family.

@en

P2093

Clifford D Mol

http://www.w3.org/2001/XMLSchema#string

Nick J Dibb

http://www.w3.org/2001/XMLSchema#string

Stephen M Dilworth

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12

The structure of phosphorylated p38gamma is monomeric and reveals a conserved activation-loop conformation

Structural basis of cyclin-dependent kinase activation by phosphorylation

Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP

The role of FLT3 in haematopoietic malignancies

The protein kinase complement of the human genome

The discovery of the alpha-helix and beta-sheet, the principal structural features of proteins

Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region

P2888

P304

718-727

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRC1434

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1022431788

http://www.w3.org/2001/XMLSchema#string

P698

15343278

http://www.w3.org/2001/XMLSchema#string